Reviva Pharmaceuticals Warrants
RVPHW
RVPHW was delisted on the 12th of December, 2025.
17 hedge funds and large institutions have $3.06M invested in Reviva Pharmaceuticals Warrants in 2020 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 1 closing their positions.
18% more capital invested
Capital invested by funds: $2.6M → $3.06M (+$462K)
0% more funds holding
Funds holding: 17 → 17 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$105K |
| 2 |
BCM
BlueCrest Capital Management
St Helier,
Jersey
|
+$32.4K |
| 3 |
BCM
Basso Capital Management
Stamford,
Connecticut
|
+$22.3K |
| 4 |
BFM
Boothbay Fund Management
New York
|
+$9.73K |
| 5 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
+$3.74K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$32K |
| 2 |
CAC
Cowen and Company
New York
|
-$7.71K |
| 3 |
BI
Bulldog Investors
Saddle Brook,
New Jersey
|
-$4.63K |
| 4 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$2.98K |
| 5 |
Walleye Trading
New York
|
-$299 |
RVPHW Hedge Fund Activity: Q1 2020 in Review
17 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Reviva Pharmaceuticals Warrants (RVPHW) for Q1 2020, worth a combined $3.06M — up 18% from $2.6M a quarter earlier.
Fund positioning in RVPHW was balanced in Q1 2020: 1 fund opened new positions, 1 closed out, 4 added to existing stakes and 4 trimmed.
The largest buyer was Hudson Bay Capital Management, adding an estimated $105K. The largest seller was Oxford Asset Management, exiting entirely with an estimated $32K sold.
- 17 institutional investors held Reviva Pharmaceuticals Warrants (RVPHW) as of Q1 2020, unchanged from Q4 2019.
- Funds reported $3.06M of Reviva Pharmaceuticals Warrants stock for Q1 2020, up 18% quarter-over-quarter.
- 1 fund opened new Reviva Pharmaceuticals Warrants positions in Q1 2020 and 1 closed out, a net change of 0 holders.
- The largest Reviva Pharmaceuticals Warrants buyer in Q1 2020 was Hudson Bay Capital Management, an estimated $105K added.
- The largest Reviva Pharmaceuticals Warrants seller in Q1 2020 was Oxford Asset Management, an estimated $32K sold.
Based on aggregated 13F filings for Q1 2020.